checkAd

     153  0 Kommentare Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market - Seite 3

    Contact for investors:
    Sebastian Frericks
    Head of Group Finance and Investor Relations
    Carl Zeiss Meditec AG
    Phone: +49 3641 220 116
    Mail: investors.meditec@zeiss.com

    Contact for the press: 

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Carl Zeiss Meditec AG!
    Long
    77,64€
    Basispreis
    0,69
    Ask
    × 11,87
    Hebel
    Short
    90,60€
    Basispreis
    0,75
    Ask
    × 11,86
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Frank E. Smith  
    Head of Global Communications Ophthalmology
    Carl Zeiss Meditec AG
    Phone: +1 925 487 3036 
    Mail: frank.smith@zeiss.com 

    www.zeiss.com/newsroom

    Company Profiles:

    Carl Zeiss Meditec AG

    Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

    The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

    For more information visit our website at www.zeiss.com/med.

    About D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.

    D.O.R.C. is one of the world's leading suppliers of equipment, instruments, and liquids for ophthalmic surgery. For 40 years, D.O.R.C. has grown into a successful international business, shaping its product portfolio through close collaboration with leading top surgeons. The company improves eye surgery globally and maximizes surgeon control by providing innovative quality approaches for eye disorders. Its products are exported to more than 80 countries worldwide. The company is headquartered in Zuidland, the Netherlands, and has more than 800 employees.

    ZEISS

    Photo - https://mma.prnewswire.com/media/2378028/DORC.jpg
    Logo - https://mma.prnewswire.com/media/546786/ZEISS_v1_Logo.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/carl-zeiss-meditec-ag-completes-acquisition-of-dutch-ophthalmic-research-center-dorc-companies-unite-to-shape-ophthalmology-market-302106574.html


    The Carl Zeiss Meditec Stock at the time of publication of the news with a fall of -0,90 % to 110EUR on Tradegate stock exchange (04. April 2024, 13:03 Uhr).
    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market - Seite 3 ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic medical devices and surgery.   JENA, Germany and …

    Schreibe Deinen Kommentar

    Disclaimer